Systemic therapy for sarcoidosis is reserved for organ-threatening disease, and laryngeal involvement necessitates treatment ...
Aging-focused biotech companies share how they're advancing therapies to slow disease, extend lifespan, and transform medicine.
The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults. Jascayd becomes the first and only preferential ...
Nerandomilast, a PDE4B inhibitor, is now FDA-approved for progressive pulmonary fibrosis, offering immunomodulatory and antifibrotic effects. The FIBRONEER-ILD trial showed nerandomilast significantly ...
Following the recent approval of nerandomilast tablets for the treatment of idiopathic pulmonary fibrosis (IPF) in adults, the FDA has approved the medication for progressive pulmonary fibrosis as ...
AI-based imaging tools have shown potential in detecting treatment responses in IPF, supporting the use of ENV-101 and AI imaging as trial endpoints. The forced oscillation technique (FOT) may enhance ...
What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is now approved for treating adults with progressive pulmonary fibrosis (PPF) that causes gradual and permanent scarring in the lungs, ...
Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient ...
Environmental factors including temperature, humidity, air quality, and seasonal changes can significantly impact idiopathic pulmonary fibrosis (IPF). These triggers can exacerbate symptoms and lead ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback